Ironwood Pharmaceuticals(NASDAQ) IRWD

Ironwood makes medicines for people with stomach issues. These drugs help patients manage pain and constipation. The company focuses on digestion and rare diseases.

What Ironwood Sells

• LINZESS: Capsule for adults and children with chronic constipation; accounts for nearly all total revenue.
• CONSTELLA: Name used for linaclotide in Canada and Europe; treats adult irritable bowel syndrome.
• Apraglutide: Peptide in development for short bowel syndrome; aims to reduce dependency on nutritional support.

Expanding the Pipeline

• Acquired VectivBio Holding AG in June 2023 to add rare disease treatments to its portfolio.
• Partnered with Asahi Kasei Pharma Corporation in March 2022 to develop and sell products in Japan.
• Reached an agreement with the U.S. FDA in late 2025 on the design of a new clinical trial.

Why Partnerships Matter

Ironwood uses a partnership model to share drug development costs and risks. This strategy allows the company to reach global markets through collaborations with larger pharmaceutical firms.

A Look at the Numbers

• Revenue was $47.7 million in Q4 2025, down 47.3% from Q4 2024.
• Operating income fell to $6.6 million in Q4 2025, down 79.2% from the previous year.
• Net income was -$2.3 million in Q4 2025, worsening from a profit of $2.3 million in Q4 2024.
• Operating cash flow reached $74.6 million in Q4 2025, up 390.2% year-over-year.

The Final Word

Ironwood has evolved from a single-product business into a developer of treatments for rare diseases. While its core product faces pricing changes, its pipeline and global partnerships support its long-term operations.